

Page 4, between lines 20 and 21, insert the following heading - Summary of the

Ε3 Invention.

Page 5, between lines 6 and 7, insert the following heading - Description of the Preferred

Embodiments.

Ε4 Page 7, line 10, insert the following:

Ε5 The present invention will now be described in more detail using the following Examples. However, the Examples are merely illustrative and should not be construed to narrow the spirit and scope of the claims.

In the Claims:

Kindly cancel claims 14, 15 and 17-29 without prejudice.

Please amend the claims as follows.

Ε6 13. (Amended) [A] An isolated peptide selected from the group consisting of the peptide of SEQ ID. No. 1 and functional variants thereof, said functional variants (i) comprising at least 6 amino acid residues, [and] (ii) having at least 70% homology with part or all of the [amino acid sequence as set forth in] peptide of SEQ ID No. 1 and (iii) retaining the calcium channel modulatory function of the peptide of SEQ ID No. 1.

Ε7 16. (Amended) A probe consisting of the peptide of claim 13, [or claim 14,] labeled with a signal moiety, or immobilized on a solid support.

Eg 30. (Amended) [A] The peptide as claimed in claim 13 [or claim 14], which peptide is a fragment of [the AChE molecule] acetylcholinesterase.

31. (Amended) [A] The peptide as claimed in claim 13 [or claim 14], which peptide has been chemically synthesized.

Please add the following new claims.

--32. The peptide as claimed in claim 13, which is the peptide of SEQ. ID No. 1.

Eg 33. A method for obtaining an antibody comprising using the peptide according to any one of claims 13, 30, 31 and 32 as an antigen to obtain said antibody.

~~Sub 34. A method of screening comprising using the peptide according to any one of claims 13, 30, 31 and 32 to screen substances which inhibit the activity of said peptide as a calcium channel modulator.--.~~

#### REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.